AMAG Pharmaceuticals (NASDAQ:AMAG) Lifted to Sell at BidaskClub

BidaskClub upgraded shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a strong sell rating to a sell rating in a research note released on Wednesday, January 24th.

A number of other analysts have also commented on AMAG. Cantor Fitzgerald reiterated a hold rating and issued a $21.00 price target on shares of AMAG Pharmaceuticals in a research note on Thursday, September 28th. Janney Montgomery Scott reiterated a hold rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Morgan Stanley reduced their price target on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an overweight rating for the company in a research note on Friday, November 3rd. B. Riley reiterated a hold rating and issued a $16.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday, January 16th. Finally, Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a hold rating to a buy rating and set a $21.00 price target for the company in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of Hold and an average price target of $19.89.

Shares of AMAG Pharmaceuticals (NASDAQ AMAG) opened at $12.95 on Wednesday. AMAG Pharmaceuticals has a 12 month low of $11.93 and a 12 month high of $25.20. The company has a market cap of $481.13, a P/E ratio of -2.13 and a beta of 0.79. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Balter Liquid Alternatives LLC purchased a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth approximately $120,000. Hartford Investment Management Co. purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $186,000. Cubist Systematic Strategies LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $197,000. 361 Capital LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $197,000. Finally, Aperio Group LLC purchased a new position in shares of AMAG Pharmaceuticals in the third quarter worth approximately $198,000.

WARNING: “AMAG Pharmaceuticals (NASDAQ:AMAG) Lifted to Sell at BidaskClub” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://ledgergazette.com/2018/02/11/amag-pharmaceuticals-amag-lifted-to-sell-at-bidaskclub.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply